Label: ZARAH- drospirenone and ethinyl estradiol kit

  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated December 15, 2020

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use ZARAH safely and effectively. See full prescribing information for ZARAH. ZARAH® (drospirenone/ethinyl estradiol) tablets, for oral ...
  • Table of Contents
    Table of Contents
  • BOXED WARNING (What is this?)

    WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS

    Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke [see Contraindications (4)].

    Close
  • 1 INDICATIONS AND USAGE
    Zarah® (drospirenone/ethinyl estradiol tablets) is indicated for use by women to prevent pregnancy.
  • 2 DOSAGE AND ADMINISTRATION
    2.1 How to Take Zarah - Take one tablet by mouth at the same time every day. The failure rate may increase when pills are missed or taken incorrectly. To achieve maximum contraceptive ...
  • 3 DOSAGE FORMS AND STRENGTHS
    Zarah (drospirenone/ethinyl estradiol) tablets are available in blister packs. Each blister pack contains 28 round, unscored tablets in the following order: 21 blue tablets each containing 3 mg ...
  • 4 CONTRAINDICATIONS
    Do not prescribe Zarah to women who are known to have the following: Renal impairment - Adrenal insufficiency - A high risk of arterial or venous thrombotic diseases. Examples include women who are ...
  • 5 WARNINGS AND PRECAUTIONS
    5.1 Thromboembolic Disorders and Other Vascular Problems - Stop Zarah if an arterial or venous thrombotic (VTE) event occurs. Based on presently available information on Zarah, DRSP-containing ...
  • 6 ADVERSE REACTIONS
    The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling: Serious cardiovascular events and stroke [see Boxed Warning and Warnings and Precautions ...
  • 7 DRUG INTERACTIONS
    Consult the labeling of all concurrently-used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations. 7.1 Effects of Other ...
  • 8 USE IN SPECIFIC POPULATIONS
    8.1 Pregnancy - There is little or no increased risk of birth defects in women who inadvertently use COCs during early pregnancy. Epidemiologic studies and meta-analyses have not found an ...
  • 10 OVERDOSAGE
    There have been no reports of serious ill effects from overdose, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea. DRSP is a spironolactone analogue ...
  • 11 DESCRIPTION
    Zarah (drospirenone/ethinyl estradiol tablets) provides an oral contraceptive regimen consisting of 28 round, unscored tablets that contain the ingredients specified for each tablet below: 21 ...
  • 12 CLINICAL PHARMACOLOGY
    12.1 Mechanism of Action - COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration ...
  • 13 NONCLINICAL TOXICOLOGY
    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility - In a 24 month oral carcinogenicity study in mice dosed with 10 mg/kg/day DRSP alone or 1 + 0.01, 3 + 0.03 and 10 + 0.1 mg/kg/day of ...
  • 14 CLINICAL STUDIES
    In the clinical efficacy studies of up to 2 years duration, 2,629 subjects completed 33,160 cycles of use without any other contraception. The mean age of the subjects was 25.5 ± 4.7 years. The ...
  • 15 REFERENCES
    Seeger, J.D., Loughlin, J., Eng, P.M., Clifford, C.R., Cutone, J., and Walker, A.M. (2007). Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives ...
  • 16 HOW SUPPLIED/STORAGE AND HANDLING
    16.1 How Supplied - Zarah (drospirenone/ethinyl estradiol tablets) is available in packages of three blister packs (NDC 51862-036-03). The tablets are round and unscored, one side is embossed ...
  • 17 PATIENT COUNSELING INFORMATION
    Advise the patient to read the FDA-approved patient labeling (Patient Information). Counsel patients that cigarette smoking increases the risk of serious cardiovascular events from COC use, and ...
  • FDA Approved Patient LabelingGuide for Using Zarah
    WARNING TO WOMEN WHO SMOKE - Do not use Zarah if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel ...
  • Zarah (3mg/0.03mg) Tablets 28-Day Regimen
    Label Image
  • INGREDIENTS AND APPEARANCE
    Product Information